-3.33%
5.15%
50.17%
37.45%
-2.65%
104.26%
144.03%
AI Spotlight on BIOA
Company Description
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden.The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease.It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries.
In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease.It has research collaboration agreement with Eisai and AbbVie.The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016.
BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Market Data
| Last Price | 220.6 |
| Change Percentage | -3.33% |
| Open | 230.6 |
| Previous Close | 228.2 |
| Market Cap ( Millions) | 19120 |
| Volume | 846921 |
| Year High | 250 |
| Year Low | 137.7 |
| M A 50 | 196.68 |
| M A 200 | 189.51 |
Financial Ratios
| FCF Yield | -0.88% |
| Dividend Yield | 0.00% |
| ROE | -23.96% |
| Debt / Equity | 6.14% |
| Net Debt / EBIDTA | 250.01% |
| Price To Book | 21.22 |
| Price Earnings Ratio | -83.7 |
| Price To FCF | -113.15 |
| Price To sales | 114.39 |
| EV / EBITDA | -84.71 |
News
- Jan -27 - Tikehau Capital And 2 More Stocks That May Be Priced Below Their Estimated Worth
- Jan -27 - 3 Growth Companies Insiders Own With Earnings Growth Up To 51%
- Jan -27 - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
- Jan -14 - FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
- Jan -09 - High Growth Tech Stocks To Watch In January 2025
- Dec -20 - Exploring Undervalued Small Caps With Insider Action In December 2024
- Dec -20 - Top Growth Stocks With Insider Backing In December 2024
- Dec -20 - 3 Stocks That May Be Trading Below Their Estimated Intrinsic Value
- Dec -11 - High Growth Tech Stocks To Watch This December 2024
- Nov -18 - 3 Undervalued Small Caps With Insider Buying Across Global Markets
- Nov -18 - Three Stocks Estimated To Be Undervalued In November 2024
- Nov -14 - CHMP issues positive recommendation for approval of lecanemab in the EU
- Nov -14 - 3 Growth Companies Insiders Are Betting On
- Nov -08 - Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
- Nov -08 - High Growth Tech Companies To Watch In November 2024
- Oct -24 - Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
- Oct -16 - 3 Swedish Growth Stocks With Up To 34% Insider Ownership
- Oct -14 - 3 Swedish Growth Stocks With High Insider Ownership Expecting Up To 98% Earnings Growth
- Oct -14 - Spotlighting 3 Swedish Growth Stocks With Strong Insider Ownership
- Oct -08 - 3 High Growth Swedish Tech Stocks To Watch
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Biological Drugs
Expected Growth : 9.27 %
What the company do ?
Innovative Biological Drugs from BioArctic AB (publ) develops novel treatments for Alzheimer's and Parkinson's diseases using its proprietary technology.
Why we expect these perspectives ?
BioArctic AB's 9.27% growth in innovative biological drugs is driven by increasing demand for Alzheimer's and Parkinson's disease treatments, strategic partnerships, and a strong pipeline of novel antibody-based therapies. Additionally, the company's focus on neurodegenerative diseases and its proprietary technology platform contribute to its growth momentum.
Bioarctic Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| BAN2401 | A immunotherapy treatment for Alzheimer's disease, targeting toxic beta-amyloid oligomers |
| SC0806 | A treatment for complete spinal cord injury, aiming to restore motor function and sensation |
| AD1502 | A diagnostic tool for early detection of Alzheimer's disease, using a blood-based biomarker |
| SC602 | A treatment for Parkinson's disease, targeting alpha-synuclein pathology |
BioArctic AB (publ)'s Porter Forces
Threat Of Substitutes
BioArctic AB (publ) has a moderate threat of substitutes due to the availability of alternative treatments for Alzheimer's disease, such as Aduhelm and Lecanemab. However, the company's focus on developing a disease-modifying therapy with a unique mechanism of action reduces the threat of substitutes.
Bargaining Power Of Customers
BioArctic AB (publ) has a low bargaining power of customers due to the lack of alternative treatments for Alzheimer's disease. The company's product, if approved, will be a first-in-class treatment, giving it significant pricing power.
Bargaining Power Of Suppliers
BioArctic AB (publ) has a low bargaining power of suppliers due to its partnership with Eisai, a large pharmaceutical company. This partnership reduces the company's dependence on suppliers and gives it greater control over its supply chain.
Threat Of New Entrants
BioArctic AB (publ) faces a high threat of new entrants due to the growing interest in Alzheimer's disease research and the potential for new companies to enter the market. However, the company's strong intellectual property position and partnership with Eisai reduce the threat of new entrants.
Intensity Of Rivalry
BioArctic AB (publ) operates in a moderately competitive market with several companies developing treatments for Alzheimer's disease. However, the company's unique approach and partnership with Eisai reduce the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.47% |
| Debt Cost | 3.95% |
| Equity Weight | 99.53% |
| Equity Cost | 3.24% |
| WACC | 3.24% |
| Leverage | 0.48% |
BioArctic AB (publ) : Quality Control
BioArctic AB (publ) passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Gubra
A-Score
1-Year Total Return ->
🥈
MediWound
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
